Yanghee Woo, MD, provides an overview of the CROSS trial which focused on treating patients with gastroesophageal junction ...

Recent advances in bladder cancer treatments may offer hope of curative care to more patients, including those with high-risk localized, muscle-invasive disease, according to an editorial published in ...

Wong, Founder and CEO of HCW Biologics, stated, “In the third quarter 2024, the Company expanded our product portfolio and possible disease indications that may be treated with our immunotherapeutic ...

Ivermectin is an antiparasitic agent, and its potential as an anticancer agent has recently attracted increasing attention.

Shares of Immutep (NASDAQ:IMMP) climbed 11% Thursday after the Australian company reported positive data from two clinical trials of its drug candidate eftilagimod alpha, or efti. Immutep (IMMP) said ...

First Immutep reported on positive data from the Phase I trial evaluating its eftilagimod alpha (efti) in combination with ...

THURSDAY, Nov. 14, 2024 (HealthDay News) -- Neoantigen DNA vaccines are safe and capable of inducing neoantigen-specific ...

Notes payable, plus accrued interest, totaled approximately $6.9 million. The current portion of the notes payable plus ...

Over the last 2 decades, significant progress has been made in our understanding of the genomics, tumor immune microenvironment, and immunogenicity of malignant melanoma. Historically, the prognosis ...

Dr. Beata Halassy, a 49-year-old virologist, self-treated her recurrent breast cancer with OVT, a method that leverages ...